Anzeige
Mehr »
Mittwoch, 01.10.2025 - Börsentäglich über 12.000 News
Globaler Gamechanger: CiTech expandiert in Europa - neue Chancen für Investoren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
246 Leser
Artikel bewerten:
(1)

Mural Health and ClinOne Partner to Maximize Patient Experience While Minimizing Site Burden

Strategic partnership integrates next-generation patient support and payment solutions for participants and sites alike

BERWYN, Pa., June 6, 2023 /PRNewswire/ -- Mural Health, a clinical trials technology company that improves the patient and caregiver experience in clinical trials, has today announced a strategic partnership with ClinOne, the leading provider of adaptive clinical trial experience solutions. The move will integrate Mural Link, a next generation patient payments and participant management platform, into ClinOne's patient support and trial management technology. The partnership will further streamline site-level operations and improve the participant journey.

Both companies are using technology to help sponsors overcome the stubborn challenges of drug development, including poor recruitment and retention, by focusing product design on the participant (the end-user). Both companies are also committed to reducing the administrative burden that clinical research sites can experience when sponsors require multiple technology platforms.

Mural Link is an innovative platform that optimizes the participant experience, strategically leveraging next-gen clinical trial payment technology, to continually engage patients and caregivers. Mural Link's novel strategy and market leading technology platform eliminates financial barriers to enrollment, improves site-level operations, and, ultimately, speeds trial execution while improving the quality of the clinical data set. ClinOne shares the same mission, providing a selection of patient engagement solutions, including consent management, medication adherence monitoring, clinic visit ride hailing, a patient and caregiver portal, and e-diaries, in a single platform.

The partnership, announced today, embeds Mural Link into ClinOne's suite of solutions, creating a seamless user experience for patients and sites alike.

"Mural Health offers a truly innovative approach to improving clinical trials," Andrea Valente, CEO at ClinOne, said. "Making participation easy and focusing on efficient study operations align with our goals. We are very excited to partner with the Mural Health team to bring a superior experience to all participants during their clinical trial journey."

Mural Health's Co-Founder and Co-CEO, Sam Whitaker said: "We are thrilled to be working with ClinOne, Andrea and her team share our values and mission. By embedding Mural Link into the ClinOne tech family, we will be able to further streamline site-level operations and empower ClinOne to improve the participant journey for studies its supports."

About Mural Health

Mural Health is a next-generation participant management platform. The Company's Mural Link technology platform is designed to make it easier to participate in clinical trials, thereby improving study operation and the quality of clinical data sets. Mural Link offers next-generation participant payment technology that gives participants the power to choose how they receive payment, eliminates predatory fees related to prepaid debit cards, introduces functionality to help patients arrive at site visits (without incurring a cash expense), empowers communication between participants and site personnel, and captures participant data to predict individuals who are likely to drop-out. The Mural Link platform can be easily deployed to positively improve participant retention and engagement, increase protocol compliance, and increase enrollment rates. Please reach out to us to learn more about or capabilities, www.muralhealth.com or general@muralhealth.com.

About ClinOne

ClinOne connects, informs and empowers patients, caregivers and sites in clinical trials with a true single platform for trial awareness, consent management and patient engagement underpinned with comprehensive data insights tools. Used by more than 80 sponsors, CROs and site networks in 60 countries, our solutions are proven to reduce risk and simplify complex processes for therapeutic areas and patient populations including Oncology, Rare Disease, Pediatrics, the Elderly and CNS. Designed in collaboration with sites and with participants and caregivers in mind, ClinOne features the industry's fastest deployment, cost-efficient scale for trials of all sizes and seamless API integrations to provide the results you need and the experience your patients deserve. Ready to keep patients, sites and study teams active and engaged throughout your clinical trial? Let's get creative at www.clinone.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/mural-health-and-clinone-partner-to-maximize-patient-experience-while-minimizing-site-burden-301843563.html

© 2023 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.